CN1376054A - 含环丙沙星和地塞米松的局部悬浮制剂 - Google Patents

含环丙沙星和地塞米松的局部悬浮制剂 Download PDF

Info

Publication number: CN1376054A
Authority: CN; China
Prior art keywords: weight; dexamethasone; compositions; ciprofloxacin; preparation
Prior art date: 1999-09-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CN00813262A

Other languages

English (en)

Chinese (zh)

Other versions

CN1158994C (zh

Inventor

O·N·辛格

H·G·柏翟特

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alcon Inc

Original Assignee

Alcon Universal Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-24

Filing date

2000-08-10

Publication date

2002-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22557406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1376054(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-10 Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd

2002-10-23 Publication of CN1376054A publication Critical patent/CN1376054A/zh

2004-07-28 Application granted granted Critical

2004-07-28 Publication of CN1158994C publication Critical patent/CN1158994C/zh

2020-08-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 41
239000000725 suspension Substances 0.000 title claims abstract description 16
238000009472 formulation Methods 0.000 title abstract description 18
NTRHYMXQWWPZDD-WKSAPEMMSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NTRHYMXQWWPZDD-WKSAPEMMSA-N 0.000 title description 5
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 36
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 22
229960003405 ciprofloxacin Drugs 0.000 claims abstract description 18
229960003957 dexamethasone Drugs 0.000 claims abstract description 17
230000000699 topical effect Effects 0.000 claims abstract description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 14
239000012744 reinforcing agent Substances 0.000 claims description 12
229920000831 ionic polymer Polymers 0.000 claims description 11
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 10
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 10
229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 10
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 10
-1 hydroxypropyl Chemical group 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 9
239000004094 surface-active agent Substances 0.000 claims description 9
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 7
239000004327 boric acid Substances 0.000 claims description 7
230000036571 hydration Effects 0.000 claims description 6
238000006703 hydration reaction Methods 0.000 claims description 6
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
239000001632 sodium acetate Substances 0.000 claims description 5
235000017281 sodium acetate Nutrition 0.000 claims description 5
XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
229940032912 zephiran Drugs 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
AKUJBENLRBOFTD-RPRRAYFGSA-N Dexamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-RPRRAYFGSA-N 0.000 claims description 2
239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
235000004443 Ricinus communis Nutrition 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
229920001400 block copolymer Polymers 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 4
239000003795 chemical substances by application Substances 0.000 claims 2
KCQUJORJVXQRST-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN KCQUJORJVXQRST-UHFFFAOYSA-N 0.000 claims 1
235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
229920000642 polymer Polymers 0.000 abstract description 2
239000012929 tonicity agent Substances 0.000 abstract description 2
239000002736 nonionic surfactant Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 description 55
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
238000004062 sedimentation Methods 0.000 description 7
239000002002 slurry Substances 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000001954 sterilising effect Effects 0.000 description 7
238000004659 sterilization and disinfection Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
241000228245 Aspergillus niger Species 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
230000002421 anti-septic effect Effects 0.000 description 6
239000003246 corticosteroid Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 5
241000222122 Candida albicans Species 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
229940095731 candida albicans Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000000498 ball milling Methods 0.000 description 2
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000707 wrist Anatomy 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229960002233 benzalkonium bromide Drugs 0.000 description 1
KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
229960001146 clobetasone Drugs 0.000 description 1
XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960004511 fludroxycortide Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
229960002422 lomefloxacin Drugs 0.000 description 1
ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
229960003744 loteprednol etabonate Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
VGTPKLINSHNZRD-UHFFFAOYSA-N oxoborinic acid Chemical compound OB=O VGTPKLINSHNZRD-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229910052726 zirconium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

CNB008132623A 1999-09-24 2000-08-10 含环丙沙星和地塞米松的局部悬浮制剂 Expired - Lifetime CN1158994C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15594299P	1999-09-24	1999-09-24
US60/155,942		1999-09-24

Publications (2)

Publication Number	Publication Date
CN1376054A true CN1376054A (zh)	2002-10-23
CN1158994C CN1158994C (zh)	2004-07-28

Family

ID=22557406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB008132623A Expired - Lifetime CN1158994C (zh)	1999-09-24	2000-08-10	含环丙沙星和地塞米松的局部悬浮制剂

Country Status (22)

Country	Link
US (2)	US6284804B1 (und)
EP (1)	EP1214056B1 (und)
JP (2)	JP2003510263A (und)
KR (1)	KR100722502B1 (und)
CN (1)	CN1158994C (und)
AR (1)	AR025661A1 (und)
AT (1)	ATE252887T1 (und)
AU (1)	AU776609B2 (und)
BR (1)	BR0014203A (und)
CA (1)	CA2379605C (und)
DE (1)	DE60006262T2 (und)
DK (1)	DK1214056T3 (und)
ES (1)	ES2207549T3 (und)
HK (1)	HK1045653B (und)
MX (1)	MXPA02003130A (und)
PL (1)	PL201130B1 (und)
PT (1)	PT1214056E (und)
SA (1)	SA00210418B1 (und)
TR (1)	TR200200737T2 (und)
TW (1)	TWI228423B (und)
WO (1)	WO2001022936A1 (und)
ZA (1)	ZA200201904B (und)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101317847B (zh) *	2007-06-06	2010-10-13	深圳市瑞谷医药技术有限公司	一种眼用或耳鼻用药物组合物及其用途
CN101970042A (zh) *	2008-02-25	2011-02-09	眼门药品公司	经由离子电渗法增强递送治疗药物至眼部组织
WO2013084194A1 (en) *	2011-12-09	2013-06-13	Lupin Limited	Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents
CN103565816A (zh) *	2012-07-25	2014-02-12	天津金耀集团有限公司	妥布霉素地塞米松滴眼液
CN107970244A (zh) *	2016-10-21	2018-05-01	武汉武药科技有限公司	一种含有环丙沙星和地塞米松的组合物及其制备方法
CN108403700A (zh) *	2018-06-12	2018-08-17	新疆生产建设兵团第师畜牧兽医工作站	一种牛呼吸道疾病治疗用复合注射液
CN111568906A (zh) *	2019-02-15	2020-08-25	诺华股份有限公司	4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
CN113144207A (zh) *	2021-02-07	2021-07-23	山西利普达医药科技有限公司	一种包括聚季铵盐-1的组合物及其应用
CN113797162A (zh) *	2020-06-17	2021-12-17	成都瑞沐生物医药科技有限公司	一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003510263A (ja) *	1999-09-24	2003-03-18	アルコン，インコーポレイテッド	シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
CA2428189A1 (en) *	2000-11-15	2002-05-23	Mainde Chandrashekhar	Pharmaceutival preparations comprising corticosteroids and antiinfective agents
WO2003004098A1 (en) *	2001-07-06	2003-01-16	Sucampo Ag	Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
JP2005504804A (ja)	2001-09-21	2005-02-17	アルコン，インコーポレイテッド	中耳感染を処置する方法
US20090215735A1 (en) *	2002-02-25	2009-08-27	Alcon, Inc.	Topical solution formulations containing a corticosteroid and a cyclodextrin
EP2277522B1 (en) *	2002-03-01	2012-11-21	UCB Manufacturing, Inc.	Methods for increasing or decreasing bone density and identifying molecules
AU2003280960A1 (en) *	2002-07-15	2004-02-02	Alcon, Inc.	Pharmaceutical compositions for otic use
US20040101506A1 (en) *	2002-11-25	2004-05-27	Fust Charles A.	Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en)	2002-11-27	2007-05-22	Regents Of The University Of Minnesota	Methods and compositions for applying pharmacologic agents to the ear
TWI335819B (en) *	2002-12-24	2011-01-11	Alcon Inc	Use of oculosurface selective glucocorticoid in the treatment of dry eye
US20070148192A1 (en) *	2003-02-21	2007-06-28	Laddha Ritu N	Stable ophthalmic composition
US20050085446A1 (en) *	2003-04-14	2005-04-21	Babu M.K. M.	Fluoroquinolone formulations and methods of making and using the same
US20040202687A1 (en) *	2003-04-14	2004-10-14	Babu M.K. Manoj	Ciprofloxacin formulations and methods of making and using the same
EP1627637A1 (en) *	2003-05-23	2006-02-22	Santen Pharmaceutical Co., Ltd.	Ophthalmic solution containing quinolone antimicrobial compound
US8940321B2 (en) *	2003-12-12	2015-01-27	Otic Pharma Ltd.	Compositions for treatment of ear disorders and methods of use thereof
WO2005055921A2 (en)	2003-12-12	2005-06-23	Eran Eilat	Compositions for treatment of ear disorders and methods of use thereof
ES2245611B1 (es) *	2004-06-29	2007-03-16	Laboratorio Reig Jofre, S.A.	Composicion farmaceutica para uso ototopico.
US20060019987A1 (en) *	2004-07-23	2006-01-26	Fust Charles A	Methods and compositions for inhibiting, destroying, and/or inactivating viruses
DE102006010643A1 (de)	2006-03-08	2007-09-13	Bayer Healthcare Aktiengesellschaft	Arzneimittel enthaltend Fluorchinolone
US20070264296A1 (en) *	2006-05-10	2007-11-15	Myntti Matthew F	Biofilm extracellular polysachharide solvating system
US7959943B2 (en) *	2006-05-10	2011-06-14	Medtronics Xomed, Inc.	Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) *	2006-05-10	2011-07-12	Medtronic Xomed, Inc.	Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) *	2006-05-10	2011-08-09	Medtronic Xomed, Inc.	Solvating system and sealant for medical use in the sinuses and nasal passages
WO2008035246A2 (en)	2006-07-28	2008-03-27	Novagali Pharma Sa	Compositions containing quaternary ammonium compounds
US8088095B2 (en) *	2007-02-08	2012-01-03	Medtronic Xomed, Inc.	Polymeric sealant for medical use
US8271101B2 (en) *	2007-08-29	2012-09-18	Advanced Bionics	Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
JP4696251B2 (ja) *	2007-12-28	2011-06-08	防衛省技術研究本部長	多剤耐性緑膿菌の単離方法並びに多剤耐性緑膿菌選択培地の作成方法
WO2009139924A2 (en) *	2008-05-14	2009-11-19	Otonomy, Inc.	Controlled release corticosteroid compositions and methods for the treatment of otic disorders
CA2727432C (en)	2008-06-12	2016-10-11	Medtronic Xomed, Inc.	Method for treating chronic wounds with an extracellular polymeric substance solvating system
US20110117189A1 (en) *	2008-07-08	2011-05-19	S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A.	Ophthalmic compositions for treating pathologies of the posterior segment of the eye
US20100016450A1 (en) *	2008-07-21	2010-01-21	Otonomy, Inc.	Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en)	2008-07-21	2012-11-27	Otonomy, Inc.	Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2346324A4 (en) *	2008-10-06	2012-10-10	Microbial Defense Systems Llc	ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
TW201023912A (en)	2008-12-05	2010-07-01	Alcon Res Ltd	Pharmaceutical suspension
US8912236B2 (en) *	2009-03-03	2014-12-16	Alcon Research, Ltd.	Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
BRPI1008920A2 (pt) *	2009-03-03	2015-08-25	Alcon Res Ltd	Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
EP2490722A4 (en) *	2009-10-21	2014-03-05	Otonomy Inc	MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
EP2366408B1 (en)	2010-03-01	2012-07-18	Laboratorios SALVAT, S.A.	Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US8916171B2 (en)	2010-04-27	2014-12-23	Topical Sinus Therapeutics, Inc.	Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis
EP2706845B1 (en)	2011-05-10	2021-06-23	Next Science IP Holdings Pty Ltd	Antimicrobial solid and methods of making and using same
EP2938327B1 (en)	2012-12-26	2017-12-06	Otic Pharma Ltd.	Foamable otic pharmaceutical compositions
US20150164882A1 (en)	2013-07-22	2015-06-18	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en)	2013-07-22	2016-09-29	Imprimis Pharmaceuticals, Inc.	Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
JP2016534121A (ja)	2013-08-27	2016-11-04	オトノミ—，インク．	小児の耳の病気の処置
US20150119371A1 (en) *	2013-10-30	2015-04-30	Micro Labs Limited	Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
KR20170021353A (ko)	2014-07-03	2017-02-27	오토노미, 인코포레이티드	시프로플록사신 조성물의 멸균
US9393243B1 (en) *	2015-07-14	2016-07-19	Nilesh Parikh	Topical Ciprofloxacin compositions
EP3452033A4 (en) *	2016-05-06	2020-02-12	Harrow IP, LLC	PHARMACEUTICAL OPHTHALMIC COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
KR102395835B1 (ko) *	2016-08-24	2022-05-10	키에시 파르마슈티시 엣스. 피. 에이.	재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제
WO2018053173A1 (en)	2016-09-16	2018-03-22	Otonomy, Inc.	Otic gel formulations for treating otitis externa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3134718A (en)	1963-12-12	1964-05-26	Schering Corp	Pregna-1,4-dienes and compositions containing same
US4670444B1 (en)	1980-09-03	1999-02-09	Bayer Ag	and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en)	1984-12-28	1993-06-29	Alcon Laboratories, Inc.	Anti-inflammatory compounds for ophthalmic use
US4686214A (en)	1985-10-30	1987-08-11	Alcon Laboratories, Inc.	Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (de)	1987-02-17	1988-08-25	Bayer Ag	Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
GB8805268D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
AU4201189A (en)	1988-08-26	1990-03-23	Alcon Laboratories, Inc.	Combination of quinolone antibiotics and steroids for topical ophthalmic use
ES2111083T3 (es)	1991-09-17	1998-03-01	Alcon Lab Inc	Composiciones que contienen antibioticos de quinolona y poli(sulfonato de estireno).
ES2065846B1 (es) *	1993-04-20	1995-10-01	Cusi Lab	Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
US5540930A (en)	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en)	1993-12-17	1995-05-30	Alcon Laboratories, Inc.	Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
JP3781792B2 (ja) *	1993-12-27	2006-05-31	千寿製薬株式会社	ジフルプレドナート含有点眼用懸濁液剤
ES2078175B1 (es)	1993-12-31	1996-10-16	Cusi Lab	Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5422116A (en) *	1994-02-18	1995-06-06	Ciba-Geigy Corporation	Liquid ophthalmic sustained release delivery system
US5843930A (en)	1995-06-06	1998-12-01	Bayer Corporation	Method of treating otitis with ciprofloxacin-hydrocortisone suspension
DE19524691A1 (de)	1995-07-06	1997-01-09	Liedtke Pharmed Gmbh	Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
KR0155950B1 (ko)	1995-08-16	1998-12-01	김광호	플라즈마 확산 제어 방법 및 그 장치
KR100508227B1 (ko)	1997-03-14	2006-03-23	센주 세이야꾸 가부시키가이샤	로테프레드놀에타보네이트수성현탁액
CA2344050A1 (en)	1998-09-30	2000-04-06	Alcon Laboratories, Inc.	Antibiotic compositions for treatment of the eye, ear and nose
AR020660A1 (es)	1998-09-30	2002-05-22	Alcon Lab Inc	Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
AR020661A1 (es)	1998-09-30	2002-05-22	Alcon Lab Inc	Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6395746B1 (en)	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
JP2003510263A (ja) *	1999-09-24	2003-03-18	アルコン，インコーポレイテッド	シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物

2000
- 2000-08-10 JP JP2001526148A patent/JP2003510263A/ja active Pending
- 2000-08-10 DE DE60006262T patent/DE60006262T2/de not_active Expired - Lifetime
- 2000-08-10 KR KR1020027003205A patent/KR100722502B1/ko active IP Right Grant
- 2000-08-10 WO PCT/US2000/021961 patent/WO2001022936A1/en active IP Right Grant
- 2000-08-10 EP EP00959213A patent/EP1214056B1/en not_active Expired - Lifetime
- 2000-08-10 MX MXPA02003130A patent/MXPA02003130A/es active IP Right Grant
- 2000-08-10 CN CNB008132623A patent/CN1158994C/zh not_active Expired - Lifetime
- 2000-08-10 AU AU70570/00A patent/AU776609B2/en not_active Expired
- 2000-08-10 PT PT00959213T patent/PT1214056E/pt unknown
- 2000-08-10 US US09/636,563 patent/US6284804B1/en not_active Expired - Lifetime
- 2000-08-10 PL PL359623A patent/PL201130B1/pl unknown
- 2000-08-10 BR BR0014203-4A patent/BR0014203A/pt not_active Application Discontinuation
- 2000-08-10 ES ES00959213T patent/ES2207549T3/es not_active Expired - Lifetime
- 2000-08-10 DK DK00959213T patent/DK1214056T3/da active
- 2000-08-10 CA CA002379605A patent/CA2379605C/en not_active Expired - Lifetime
- 2000-08-10 TR TR2002/00737T patent/TR200200737T2/xx unknown
- 2000-08-10 AT AT00959213T patent/ATE252887T1/de active
- 2000-08-28 TW TW089117377A patent/TWI228423B/zh not_active IP Right Cessation
- 2000-09-14 AR ARP000104822A patent/AR025661A1/es unknown
- 2000-10-03 SA SA00210418A patent/SA00210418B1/ar unknown
2001
- 2001-05-25 US US09/865,783 patent/US6359016B2/en not_active Expired - Lifetime
2002
- 2002-03-07 ZA ZA200201904A patent/ZA200201904B/en unknown
- 2002-09-27 HK HK02107186.7A patent/HK1045653B/zh not_active IP Right Cessation
2010
- 2010-11-18 JP JP2010258386A patent/JP2011032293A/ja not_active Withdrawn

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101317847B (zh) *	2007-06-06	2010-10-13	深圳市瑞谷医药技术有限公司	一种眼用或耳鼻用药物组合物及其用途
CN101970042A (zh) *	2008-02-25	2011-02-09	眼门药品公司	经由离子电渗法增强递送治疗药物至眼部组织
US9149525B2 (en)	2008-02-25	2015-10-06	Eyegate Pharmaceuticals, Inc.	Delivery of corticosteroids through iontophoresis
US9820935B2 (en)	2008-02-25	2017-11-21	Eyegate Pharmaceuticals, Inc.	Delivery of corticosteroids through iontophoresis
WO2013084194A1 (en) *	2011-12-09	2013-06-13	Lupin Limited	Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents
CN103565816A (zh) *	2012-07-25	2014-02-12	天津金耀集团有限公司	妥布霉素地塞米松滴眼液
CN107970244A (zh) *	2016-10-21	2018-05-01	武汉武药科技有限公司	一种含有环丙沙星和地塞米松的组合物及其制备方法
CN107970244B (zh) *	2016-10-21	2020-07-14	武汉武药科技有限公司	一种含有环丙沙星和地塞米松的组合物及其制备方法
CN108403700A (zh) *	2018-06-12	2018-08-17	新疆生产建设兵团第师畜牧兽医工作站	一种牛呼吸道疾病治疗用复合注射液
CN111568906A (zh) *	2019-02-15	2020-08-25	诺华股份有限公司	4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
CN111568906B (zh) *	2019-02-15	2023-09-01	诺华股份有限公司	4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
CN113797162A (zh) *	2020-06-17	2021-12-17	成都瑞沐生物医药科技有限公司	一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
CN113144207A (zh) *	2021-02-07	2021-07-23	山西利普达医药科技有限公司	一种包括聚季铵盐-1的组合物及其应用

Also Published As

Publication number	Publication date
ZA200201904B (en)	2003-05-28
DK1214056T3 (da)	2004-02-09
CA2379605A1 (en)	2001-04-05
JP2003510263A (ja)	2003-03-18
PT1214056E (pt)	2004-02-27
EP1214056A1 (en)	2002-06-19
US6359016B2 (en)	2002-03-19
WO2001022936A8 (en)	2002-01-24
PL201130B1 (pl)	2009-03-31
JP2011032293A (ja)	2011-02-17
CN1158994C (zh)	2004-07-28
KR20020069508A (ko)	2002-09-04
DE60006262D1 (de)	2003-12-04
US20010034339A1 (en)	2001-10-25
AU7057000A (en)	2001-04-30
EP1214056B1 (en)	2003-10-29
ES2207549T3 (es)	2004-06-01
AU776609B2 (en)	2004-09-16
SA00210418B1 (ar)	2006-04-22
TWI228423B (en)	2005-03-01
US6284804B1 (en)	2001-09-04
PL359623A1 (en)	2004-08-23
KR100722502B1 (ko)	2007-05-28
DE60006262T2 (de)	2004-05-13
CA2379605C (en)	2007-06-26
WO2001022936A1 (en)	2001-04-05
TR200200737T2 (tr)	2002-08-21
AR025661A1 (es)	2002-12-11
BR0014203A (pt)	2002-05-21
MXPA02003130A (es)	2004-04-21
ATE252887T1 (de)	2003-11-15
HK1045653B (zh)	2004-01-30
HK1045653A1 (en)	2002-12-06

Legal Events

Date	Code	Title	Description
2002-10-02	C10	Entry into substantive examination
2002-10-02	SE01	Entry into force of request for substantive examination
2002-10-23	C06	Publication
2002-10-23	PB01	Publication
2003-01-08	C10	Entry into substantive examination
2003-01-08	SE01	Entry into force of request for substantive examination
2004-07-28	C14	Grant of patent or utility model
2004-07-28	GR01	Patent grant
2020-01-07	TR01	Transfer of patent right
2020-01-07	TR01	Transfer of patent right	Effective date of registration: 20191218 Address after: Basel Patentee after: Novartis Co., Ltd. Address before: Hananberg, Switzerland Patentee before: Alcon Company
2020-01-10	TR01	Transfer of patent right
2020-01-10	TR01	Transfer of patent right	Effective date of registration: 20191223 Address after: Fribourg Patentee after: Alcon Company Address before: Basel Patentee before: Novartis Co., Ltd.
2020-09-04	CX01	Expiry of patent term
2020-09-04	CX01	Expiry of patent term	Granted publication date: 20040728

Publication	Publication Date	Title
CN1158994C (zh)	2004-07-28	含环丙沙星和地塞米松的局部悬浮制剂
JP5698857B2 (ja)	2015-04-08	テルペノイドを含有するソフトコンタクトレンズ用眼科組成物
CN1211125C (zh)	2005-07-20	局部给药的盐酸奥洛他定制剂
EP2364137B1 (en)	2017-03-29	Pharmaceutical suspension
CN1302201A (zh)	2001-07-04	含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
TWI324925B (en)	2010-05-21	Ophthalmic composition
AU2001277891A1 (en)	2002-02-05	Pharmaceutical suspension compositions lacking a polymeric suspending agent
CA2064160C (en)	1998-08-11	Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
HUE025838T2 (en)	2016-04-28	Nanoparticulate suspensions containing carboxyvinyl polymer
US20100234336A1 (en)	2010-09-16	Ophthalmic Compositions
CN1665517A (zh)	2005-09-07	含有环索奈德的无菌水性混悬剂
JP2010265261A (ja)	2010-11-25	レボカバスチン懸濁型点眼剤
CN1063944C (zh)	2001-04-04	眼用复方妥布霉素混悬液的制法
JP2020203884A (ja)	2020-12-24	アジスロマイシンを含む製剤の品質管理
US20120028947A1 (en)	2012-02-02	Ophthalmic Compositions
JP5794977B2 (ja)	2015-10-14	アニオン性治療剤を含む水性眼用組成物
KR20230092814A (ko)	2023-06-26	브린졸라미드 및 티몰롤을 함유하는 투명 복합점안제
KR20220161379A (ko)	2022-12-06	수지제 용기에 충전된 은염 함유 안과용 수성 조성물
JPS6067468A (ja)	1985-04-17	新規な注射用組成物